pharma · Juvenile Neuronal Ceroid Lipofuscinosis · PLYX
Polaryx Therapeutics
Polaryx Therapeutics is a pharma organization headquartered in Paramus, USA. It trades on NYSE under ticker PLYX. Primary therapeutic focus areas include Juvenile Neuronal Ceroid Lipofuscinosis. NovaPharmaNews links 1 cl
Paramus, USA HQ
2014 Founded
9 Employees
Public company Type
PLYX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Paramus, USA
- Founded
- 2014
- Employees
- 9
- Programs
- 1
- Drugs
- 0
- Patents
- 0
PLX-200
Phase 3 · small molecule · Juvenile Neuronal Ceroid Lipofuscinosis
PLX-200 for Juvenile Neuronal Ceroid Lipofuscinosis is a Phase 3 program (small_molecule) at Polaryx Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code PLX-200-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Polaryx Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Juvenile Neuronal Ceroid Lipofuscinosis
- Status
- active
- Trials
- 1